Leerink reiterated an Outperform rating and $90 price target on Exact Sciences (EXAS) after the U.S. Supreme Court upheld the U.S. Preventive Services Task Force coverage mandate, a positive for Exact Sciences. This mandate has required commercial insurance to cover Cologuard without cost sharing, the analyst tells investors in a research note. The firm believes the outcome was in question but still reachable, and that the stock should find relief on Friday, as this resolves one of the main negative risks to the company and its commercial execution.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Supreme Court keeps element of Obamacare preventive care, Reuters reports
- Exact Sciences price target lowered to $65 from $75 at Barclays
- Exact Sciences Shareholders Approve 2025 Incentive Plan
- Exact Sciences’ Growth Potential Boosted by NCCN Guideline Inclusion and Expanding Market Reach
- Exact Sciences to present new positive data on Oncodetect in colorectal cancer